<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83620">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016716</url>
  </required_header>
  <id_info>
    <org_study_id>20120156</org_study_id>
    <nct_id>NCT02016716</nct_id>
  </id_info>
  <brief_title>A Randomized Phase 3 Study to Evaluate 2 Different Formulations of Romosozumab in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate 2 Different Formulations of Romosozumab in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study is to evaluate the 2 formulations of Romosozumab (AMG785) in
      Postmenopausal Women With Osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the percent change from baseline in DXA BMD at the lumbar spine (noninferiority)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint is the percent change from baseline in DXA BMD at the lumbar spine (noninferiority)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline in DXA BMD at the total hip</measure>
    <time_frame>Month 6</time_frame>
    <description>percent change from baseline in DXA BMD at the total hip • percent change from baseline in DXA BMD at the femoral neck • percent change from baseline in BTMs P1NP and CTX</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>romo A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>romosozumab formulation A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo formulation A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>romo B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>romosozumab formulation B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo formulation B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Romosozumab formulation A</description>
    <arm_group_label>romo A</arm_group_label>
    <other_name>AMG785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Romosozumab formulation A</description>
    <arm_group_label>placebo A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Romosozumab formulation B</description>
    <arm_group_label>romo B</arm_group_label>
    <other_name>AMG785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Romosozumab formulation B</description>
    <arm_group_label>placebo B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Postmenopausal women with osteoporosis at high risk for fracture defined as

          -  BMD T-score ≤ -2.50 at the lumbar spine, total hip, or femoral neck AND

          -  a history of fragility fracture or at least 2 other risk factors

        Exclusion Criteria:

          -  BMD T score &lt; -3.50 at the total hip or femoral neck.

          -  History of hip fracture.

          -  History of metabolic or bone disease (except osteoporosis).

          -  Use of agents affecting bone metabolism.

          -  Vitamin D insufficiency.

          -  History of solid organ or bone marrow transplants.

          -  Hyper- or hypocalcemia.

          -  Hyper- or hypothyroidism.

          -  Hyper- or hypoparathyroidism.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klatovy</city>
        <zip>339 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 22, 2015</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <firstreceived_results_disposition_date>June 22, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopausal Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
